Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$90.18
-0.6%
$82.44
$58.50
$98.43
$116.08B0.628.55 million shs5.15 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,065.48
-1.3%
$959.18
$623.78
$1,149.10
$1.04T0.533.10 million shs2.69 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.82
-2.7%
$41.12
$35.12
$81.44
$196.77B0.7813.81 million shs12.95 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
-0.29%-2.72%+10.45%+12.80%+41.75%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.30%+1.25%+11.89%+7.21%+46.27%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-3.42%-1.99%+0.39%+19.99%-38.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$90.18
-0.6%
$82.44
$58.50
$98.43
$116.08B0.628.55 million shs5.15 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,065.48
-1.3%
$959.18
$623.78
$1,149.10
$1.04T0.533.10 million shs2.69 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.82
-2.7%
$41.12
$35.12
$81.44
$196.77B0.7813.81 million shs12.95 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
-0.29%-2.72%+10.45%+12.80%+41.75%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.30%+1.25%+11.89%+7.21%+46.27%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-3.42%-1.99%+0.39%+19.99%-38.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVS Health Corporation stock logo
CVS
CVS Health
2.85
Moderate Buy$99.6810.53% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0015.16% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5653.11% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, and CVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/1/2026
CVS Health Corporation stock logo
CVS
CVS Health
Reiterated RatingOverweight$113.00
6/1/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetBuy$102.00 ➝ $108.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/26/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetOverweight$101.00 ➝ $106.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$1,300.00 ➝ $1,330.00
5/20/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetOutperform$102.00 ➝ $110.00
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVS Health Corporation stock logo
CVS
CVS Health
$402.07B0.29$14.76 per share6.11$59.38 per share1.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.39$24.24 per share43.96$28.07 per share37.96
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$327.80B0.58$4.41 per share9.72$6.58 per share6.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVS Health Corporation stock logo
CVS
CVS Health
$1.77B$2.2739.8710.800.890.72%11.88%3.54%7/30/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1538.0324.041.2134.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.2112.454.0637.23%63.31%22.19%8/5/2026 (Estimated)

Latest LLY, NVO, and CVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
CVS Health Corporation stock logo
CVS
CVS Health
$2.21$2.57+$0.36$2.30$94.99 billion$100.43 billion
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CVS Health Corporation stock logo
CVS
CVS Health
$2.662.95%+5.87%117.18%4 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.65%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.744.06%+21.74%40.85%N/A

Latest LLY, NVO, and CVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
3/18/2026
CVS Health Corporation stock logo
CVS
CVS Health
quarterly$0.66503.37%4/23/20264/23/20265/4/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVS Health Corporation stock logo
CVS
CVS Health
0.78
0.87
0.66
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
CVS Health Corporation stock logo
CVS
CVS Health
80.66%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
CVS Health Corporation stock logo
CVS
CVS Health
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVS Health Corporation stock logo
CVS
CVS Health
300,0001.28 billion1.27 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

A stylized digital tunnel lined with glowing stock charts, circuit patterns, and scrolling financial data.
5 Best Growth Stocks for the Next 10 Years (NVO)
...
Is Eli Lilly Starting an Nvidia-Style Run?
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
CVS Restores Coverage for Lilly's Zepbound

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CVS Health stock logo

CVS Health NYSE:CVS

$90.18 -0.52 (-0.57%)
As of 01:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,065.48 -14.48 (-1.34%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$42.82 -1.19 (-2.71%)
As of 01:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.